NIAID funded four collaborative Centers of Excellence for Translational Research (CETR) in 2025 to advance the development of medical countermeasures for known or emerging resistant bacteria and fungi. Each Center involves multidisciplinary efforts spanning early basic research through late-stage preclinical activities.
NIAID first established the CETR program in 2014 to support the discovery and development of new or improved vaccines, therapeutics, and diagnostics for emerging and re-emerging infectious diseases. The 2025 CETRs were funded with a focus on pathogens that have developed antimicrobial resistance (AMR). Each multi-project Center is organized around specific themes that address the development of a targeted medical countermeasure or technology, and related regulatory barriers.
Main Areas of Focus
- To advance the development of therapeutics, immunotherapeutics, vaccines, vaccine technologies, and in vitro diagnostics for known or emerging resistant bacteria and fungi.
Awardees
Accelerator for the Rapid Development of Countermeasures Targeting Drug-Resistant Fungal Pathogens
Institute: Johns Hopkins University
Principal Investigators (PIs): Arturo Casedevall, David Perlin
Award: U19AI189183
NIAID Contact: Ashish K. Pathak, Ph.D., Office of Translational Innovation for Product Development (OTIPD)
Center for Accelerated Development of Drug Candidates Targeting High-Threat Bacterial Infections
Institute: Hackensack University
PI: David Perlin
Award: U19AI189168
NIAID Contact: Ashish K. Pathak, Ph.D., OTIPD
Center for Immunological Intervention against Gonorrhea (CIIG)
Institute: Henry M. Jackson Foundation
PI: Ann Jerse
Award: U19AI189178
NIAID Contact: Rajan P. Adhikari, Ph.D., OTIPD
Immunization Against Multidrug-Resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)
Institute: Boston Children’s Hospital
PIs: Richard Malley, Jay Kolls, Gregory Priebe
Award: U19AI189176
NIAID Contact: Patrick Sanz, Ph.D., OTIPD